CytomX Therapeutics Initiates Dosing in Early-Stage Study Of Solid Tumor Settings
CytomX Therapeutics, Inc. (NASDAQ: CTMX) initiated enrolment by dosing first patient in a Phase 1 dose-escalation study of CX-904 for patients with advanced solid tumors.
CytomX Therapeutics Announces First Patient Dosed With CX-904 In Phase 1 Study In Patients With Advanced Solid Tumors
CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that the first patient has been dosed in a Phase 1 dose-escalation study of CX-904
CytomX Therapeutics Q1 EPS $(0.37) Misses $(0.36) Estimate, Sales $17.10M Miss $20.66M Estimate
CytomX Therapeutics (NASDAQ:CTMX) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $(0.36) by 2.78 percent. This is a 42.31 percent decrease over losses of $(0.26) per share
Earnings Scheduled For May 5, 2022
Companies Reporting Before The Bell
• Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million.
Stocks That Hit 52-Week Lows On Wednesday
Wednesday's session saw 784 companies set new 52-week lows.
